Epstein-Barr virus infection
Therapeutic area
Infectious Disease
Rare disease
No
- Definition
- An infection that is caused by Epstein-Barr virus.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Epstein-Barr virus infection
- Therapeutic area
- Infectious Disease
- Epstein-Barr virus infection
- EBV infection
- Epstein-Barr Virus infection
- Human gammaherpesvirus 4 caused disease or disorder
- Human gammaherpesvirus 4 disease or disorder
- Human gammaherpesvirus 4 infectious disease
- EBV infections
- Epstein Barr Virus infections
- Herpesvirus 4 infections, Human
- Human Herpes Virus 4 infections
- Human Herpesvirus 4 infections
- Virus infections, Epstein-Barr
- infections, EBV
- infections, Epstein-Barr Virus
- Disease mechanisms
- Acquired
- All therapeutic areas
- Infectious Disease
- Severity
- Mild
- MONDO ID
- MONDO:0005111
- Parent condition
- MONDO:0005794
Related records
Broader conditions (8)
- Disease
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Herpesviridae infectious disease
- Human disease
- Infectious disease
- Primary viral infectious disease
- Viral infectious disease
Narrower conditions (2)
- Epstein-Barr virus hepatitis
- Infectious mononucleosis
Trials (166)
- "Xijiang Project" Screening Cohort for NPC
- A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites of Nasopharyngeal Carcinoma.
- A Longitudinal Study of Epstein-Barr Virus (EBV) Reactivation in Adults Aged 18 to 29 Years
- A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3
- A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma
- A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)
- A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma
- A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma
- A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients
- A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA
- A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin
- A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age
- A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults
- A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants
- A Study of Patients With AIDS Syndrome
- A Study of the Safety and Efficacy of EBV Specific T-cell Lines
- A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
- A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Approved drugs (1)
- Tabelecleucel
Drugs in development (5)
- 14G2A Phase 1
- Lenalidomide Phase 3
- Rituximab Phase 2
- Toripalimab Early phase 1
- Traxivitug Phase 1